Skip to content
Home
Free Newsletter
Reports
All Products
Custom Reports
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Drug the Undruggable Technologies
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
Free reports
Offers
Press Room
About Us
Contact us
Home
/
Reports
/
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
